Company ProfileWe are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
|Recent Press Releases||More >>|
|07/19/17||Akcea Therapeutics Announces Closing of Initial Public Offering|
|CAMBRIDGE, Mass., July 19, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the closing of its initial public offering of 17,968,750 shares common stock at a public offering price of $8.00 per share, including 2,343,750 shares of common stock issued upon full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the offering were $143.8 million before deducting underwriting discounts and commissions and offering expenses to be paid by A... |
|07/17/17||Ionis Earns $10 Million Milestone Payment from Biogen for Advancing a New Program in its Neurology Collaboration|
|CARLSBAD, Calif., July 17, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. Ionis and Biogen have a broad strategic collaboration to develop drugs to treat patients with neurological disorders. Ionis will continue to evaluate this newest target with the goal of advancing this program into development.
"We continue to make... |
|07/13/17||Akcea Therapeutics Announces Pricing of Initial Public Offering|
|CAMBRIDGE, Mass., July 13, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the pricing of its initial public offering of 15,625,000 shares common stock at a public offering price of $8.00 per share, for gross proceeds of $125.0 million before underwriting discounts and commissions and offering expenses to be paid by Akcea. In addition, Akcea has granted the underwriters a 30-day option to purchase up to 2,343,750 additional shares of common stock at the public offering price, less... |
|07/10/17||New Data Presented at Peripheral Nerve Society Meeting Further Support Potential Benefit of Inotersen|
|Significant benefit observed for both clinical measurements of neurological disease progression and quality of life at 8 and 15 months in patients with FAP
CARLSBAD, Calif., July 10, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) presented new top-line data from the Phase 3 NEURO-TTR study of inotersen in patients with familial amyloid polyneuropathy (FAP) at the 2017 Peripheral Nerve Society Meeting. Results from the study demonstrated benefit across both primary endpoints o... |
|There are currently no events scheduled.|
For more information requests, please visit our Information Request page.
If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.
Data provided by Nasdaq. Minimum 15 minutes delayed.